National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Catharine M. Sturgeon(Edinburgh Royal Infirmary), Eleftherios P. Diamandis(Lunenfeld-Tanenbaum Research Institute), Carsten Stephan(Charité - Universitätsmedizin Berlin), Rafael Molina(Hospital Clínic de Barcelona), Nadia Harbeck(Breast Center), Barry L. Dowell(Abbott Fund), Ulf‐Håkan Stenman(University of Helsinki), Caj Haglund(University of Helsinki), Hans Lilja(Memorial Sloan Kettering Cancer Center), Mads Holten-Andersen(University of Oslo), Robert C. Bast(The University of Texas MD Anderson Cancer Center), Michael J. Duffy(University College Dublin), Daniel F. Hayes(University of Michigan–Ann Arbor), Harry G. Rittenhouse, Hans Jørgen Nielsen(Gigtforeningen), Nils Brünner(University of Copenhagen), Francisco J. Esteva(Northwell Health), Axel Semjonow, Richard J. Babaian(The University of Texas MD Anderson Cancer Center), Daniel W. Chan(Johns Hopkins University), Paul Sibley(Siemens (United Kingdom)), R. Lamerz(LMU Klinikum), Ie‐Ming Shih(Johns Hopkins University), George G. Klee(Mayo Clinic), Barry Hoffman(Mount Sinai Hospital), Lori J. Sokoll(Johns Hopkins University), György Sölétormos(University of Copenhagen), Leendert H. J. Looijenga(University Medical Center Utrecht)
Cited by 1,134
Related Papers
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k